Cite
HARVARD Citation
Romero-Laorden, N. et al. (2018). Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). British journal of cancer. 119 (9), pp. 1052-1059. [Online].